Suppr超能文献

评估无抗生素时的耐药性可逆转性及其与耐药基因适应代价的关系:以 mcr-1 为例的遗传研究。

Assessment of the reversibility of resistance in the absence of antibiotics and its relationship with the resistance gene's fitness cost: a genetic study with mcr-1.

机构信息

Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China; Key Laboratory of Tropical Disease Control, Ministry of Education, Sun Yat-sen University, Guangzhou, Guangdong, China; Department of Genetics and Biomedical Informatics, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.

Advanced Medical Technology Center, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China; Department of Genetics and Biomedical Informatics, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China; Department of Immunology and Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.

出版信息

Lancet Microbe. 2024 Aug;5(8):100846. doi: 10.1016/S2666-5247(24)00052-1. Epub 2024 Jun 10.

Abstract

BACKGROUND

The intensive use of antibiotics has resulted in strong natural selection for the evolution of antimicrobial resistance (AMR), but whether, and under what circumstances, the removal of antibiotics would result in a rapid reduction in AMR has been insufficiently explored. We aimed to test the hypothesis that in the simple, yet common, case of AMR conferred by a single gene, removing antibiotics would quickly reduce the prevalence of resistance if the AMR gene imposes a high fitness cost and costless resistance is extremely rare among its proximal mutants.

METHODS

In this genetic study, to test our hypothesis, we used the mcr-1 gene in Escherichia coli, which confers resistance to the last-resort antibiotic colistin, as a model. A high-throughput reverse genetics approach was used to evaluate mcr-1 variants for their fitness cost and resistance levels relative to a non-functional construct, by measuring relative growth rates in colistin-free media and at 2 μg/mL and 4 μg/mL colistin. We identified costless resistant mcr-1 mutants, and examined their properties within the context of the sequential organisation of mcr-1's functional domains as well as the evolutionary accessibility of these mutations. Finally, a simple population genetic model incorporating the measured fitness cost was constructed and tested against previously published real-world data of mcr-1 prevalence in colonised inpatients in China since the 2017 colistin ban in fodder additives.

FINDINGS

We estimated the relative growth rates of 14 742 mcr-1 E coli variants (including the wild type), 3449 of which were single-nucleotide mutants. E coli showed 73·8% less growth per 24 h when carrying wild-type mcr-1 compared with the non-functional construct. 6252 (42·4%) of 14 741 mcr-1 mutants showed colistin resistance accompanied by significant fitness costs, when grown under 4 μg/mL colistin selection. 43 (0·3%) mcr-1 mutants exhibited costless resistance, most of which contained multiple mutations. Among the 3449 single mutants of mcr-1, 3433 (99·5%) had a fitness cost when grown in colistin-free media, with a mean relative growth of 0·305 (SD 0·193) compared with the non-functional variant. 3059 (88·7%) and 1833 (53·1%) of 3449 single mutants outgrew the non-functional mcr-1 in the presence of 2 μg/mL and 4 μg/mL colistin, respectively. Single mutations that gave rise to costless mutants were rare in all three domains of mcr-1 (transmembrane domain, flexible linker, and catalytic domain), but the linker domain was enriched with cost-reducing and resistance-enhancing mutations and depleted with cost-increasing mutations. The population genetics model based on the experimental data accurately predicts the rapid decline in mcr-1 prevalence in real-world data.

INTERPRETATION

Many identified costless resistant variants that consist of multiple mutations are unlikely to evolve easily in nature. These findings for colistin and mcr-1 might be applicable to other cases in which AMR entails a substantial fitness cost that cannot be mitigated in proximal mutants.

FUNDING

National Natural Science Foundation of China, and National Key Research and Development Program of China.

摘要

背景

抗生素的大量使用导致了抗菌药物耐药性(AMR)的强烈自然选择,但抗生素的去除是否以及在什么情况下会导致 AMR 迅速减少,这一点尚未得到充分探索。我们旨在检验以下假设:在由单个基因赋予的简单而常见的 AMR 情况下,如果 AMR 基因带来高适应性成本,并且其近缘突变体中几乎不存在无代价的耐药性,那么去除抗生素将迅速降低耐药性的流行率。

方法

在这项遗传研究中,为了检验我们的假设,我们使用大肠杆菌中的 mcr-1 基因作为模型,该基因赋予对最后一道防线抗生素黏菌素的耐药性。我们使用高通量反向遗传学方法,通过在无黏菌素培养基中和 2μg/mL 和 4μg/mL 黏菌素中测量相对生长速率,来评估 mcr-1 变体的适应性成本和耐药水平,相对于无功能构建体。我们确定了无代价耐药的 mcr-1 突变体,并在 mcr-1 功能域的连续组织以及这些突变的进化可及性的背景下研究了它们的特性。最后,构建了一个简单的种群遗传模型,该模型纳入了测量的适应性成本,并与中国自 2017 年禁止在饲料添加剂中使用黏菌素以来,在住院患者中进行的 mcr-1 流行率的先前发表的真实世界数据进行了对比。

发现

我们估计了 14742 个 mcr-1 大肠杆菌变体(包括野生型)的相对生长速率,其中 3449 个是单核苷酸突变体。与无功能构建体相比,携带野生型 mcr-1 的大肠杆菌每 24 小时的生长速度下降了 73.8%。在 4μg/mL 黏菌素选择下,当生长在 4μg/mL 黏菌素下时,有 6252(42.4%)个 mcr-1 突变体表现出黏菌素耐药性,并伴有显著的适应性成本。有 43(0.3%)个 mcr-1 突变体表现出无代价的耐药性,其中大多数含有多个突变。在 mcr-1 的 3449 个单突变体中,有 3433(99.5%)个在无黏菌素培养基中生长时有适应性成本,与无功能变体相比,相对生长率为 0.305(标准差 0.193)。在 2μg/mL 和 4μg/mL 黏菌素存在的情况下,有 3059(88.7%)和 1833(53.1%)个 mcr-1 单突变体的生长速度超过了无功能的 mcr-1。在 mcr-1 的三个结构域(跨膜域、柔性连接子和催化域)中,产生无代价突变体的单突变体都很罕见,但连接子域富含降低成本和增强耐药性的突变体,而缺乏增加成本的突变体。基于实验数据的种群遗传模型准确地预测了真实世界数据中 mcr-1 流行率的迅速下降。

解释

许多鉴定出的无代价耐药变体由多个突变组成,在自然界中不易进化。这些关于黏菌素和 mcr-1 的发现可能适用于其他情况,即 AMR 涉及到不能在近缘突变体中减轻的大量适应性成本。

结论

许多鉴定出的无代价耐药变体由多个突变组成,在自然界中不易进化。这些关于黏菌素和 mcr-1 的发现可能适用于其他情况,即 AMR 涉及到不能在近缘突变体中减轻的大量适应性成本。

资助

国家自然科学基金和国家重点研发计划。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验